SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mad2 who wrote (176)4/4/2000 11:26:00 AM
From: Hank  Read Replies (1) of 207
 
Actually, the real news behind GUMM's last PR release was:

``We are very pleased with our launch of Zicam(TM) Cold Remedy this cold season. Although we did not begin our marketing campaign until November and were in a back
order situation from November until mid-January, Zicam(TM) Cold Remedy was among the top selling products in the cough & cold category this cold season. The delay in
keeping product fully stocked on the shelves in December, coupled with a very short cold season, which peaked in early January and declined much more rapidly than
normal in January, February and March, limited our ability to fully realize during the 1999-2000 cold season what we believe is the significant market potential of Zicam(TM)
Cold Remedy. The very short cold season in particular limited the level of reorders during the first quarter.'"

The Allergy Relief scam was just a smoke screen designed to downplay the fact that they are STILL losing money and Ziscam sales were poor.

The statement that Ziscam Allergy Relief is "designed to provide temporary relief" means that you can't sneeze as long as you have a squirt bottle jammed up your nose.

Don't hold your breath looking for published clinical's on the Allergy crap. No journal in existence, not even the crummy ones, would publish that nonsense. Of course, GUMM can say whatever they want about the clinical trials (assuming there even were any) since neither the FDA nor the FTC feels inclined to review the accuracy of their data-so far.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News